News

BMD Dips, Then Plateaus Following Gastric Bypass


 

CHICAGO — In one of the first studies to examine the long-term endocrine effects of gastric bypass surgery, it appears that after a loss in the first year post procedure, bone mineral density recovers in succeeding years, researchers reported at the annual meeting of the Society for Surgery of the Alimentary Tract.

Surgeons at Virginia Commonwealth University in Richmond prospectively collected data on 233 patients who were undergoing gastric bypass surgery. Of those, 82% had a Roux-en-Y procedure, 12% laparoscopically. The average age was 40 years, and the average body mass index was 50 kg/m

Dr. Johnson and his colleagues obtained preoperative bone mineral density (BMD) scans and found that most patients were normal at baseline, and remained at normal levels, even after surgery. Fifteen patients were osteopenic at baseline. Three developed osteopenia at 1 year post procedure. One patient with preoperative osteopenia actually had an increase in BMD after surgery.

At 1 year, for all patients, total forearm BMD decreased by 0.55%, and radius BMD increased by 1.85%. Total hip and lumbar spine BMD declined by 9.27% and 4.53%, respectively. These seem like fairly large decreases, but none of the patients developed osteoporosis during this period, Dr. Johnson said. The figures suggest a decline in the first year after gastric bypass, but the clinical significance of this is not yet known, he added.

At 2 years, forearm BMD decreased by 3.62%, but radius BMD remained steady. Both total hip and lumbar spine BMD recovered somewhat in the second year, bringing them to almost the same levels as preoperatively.

At 3 and 4 years after surgery, BMD trended up, but there were too few patients at those time points to determine if the increases were statistically significant, Dr. Johnson said.

About 50%–60% of patients had calcium, parathyroid hormone, and vitamin D levels taken before surgery; all had those elements measured annually thereafter.

The mean serum calcium decreased from 9.8 mg/dL at baseline to 9.2 mg/dL in the first year, and to 8.8 mg/dL in the second year.

Although the study backed other reports showing an initial decline in BMD, the clinical significance is not known, Dr. Johnson said. “We have shown it's not an ongoing process,” he added.

Recommended Reading

Once-Monthly Ibandronate Effective at 2 Years
MDedge Rheumatology
Patients Taking Steroids Require Multiple Bone-Saving Measures
MDedge Rheumatology
Alendronate Bests Alfacalcidol in Steroid-Induced Osteoporosis
MDedge Rheumatology
German Study Results Back Balloon Kyphoplasty
MDedge Rheumatology
Check Eyesight to Cut Fracture Risk in Osteoporotic Patients
MDedge Rheumatology
Don't Miss Vitamin D Deficiency in Osteoporotics : More than 50% of women being treated for the bone disorder had serum D levels lower than 30 ng/mL.
MDedge Rheumatology
In Paget's Disease Patients, Zoledronic Acid Packs a Bigger Punch Than Oral Risedronate
MDedge Rheumatology
Strontium Ranelate Prevents Fractures in Highest-Risk Women
MDedge Rheumatology
Folate, B12 After Stroke Prevents Bone Fractures
MDedge Rheumatology
New Tool Will Calculate Absolute Fracture Risk
MDedge Rheumatology